3. Umbruch 4.4..2005 - Online Pot

Cannabinoids in appetite and obesity 229
4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of
the CB1 cannabinoid receptor: biochemical and pharmacological characterizaztion. J Pharmacol
Exp Ther 310: 905–914
38 Fong MT, Goulet M, Hagman W, Plummer C, Finke P, Mills S, Shah S, Truong Q., Shen C, Lao,
J, Van der Ploeg L (2003) Biological and pharmacological activity of new CB1R inverse agonist,
2003 Symposium on the Cannabinoids p 1, International Cannabinoid Research Society,
Burlington, Vermont
39 Smith R.A, O’Connor SJ, Wirtz SN, Wong WC, Choi S, Kluender HC, Su N, Wang G, Achebe F,
Ying S (2003) Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatment
of obesity. International Patent Application WO 03/040107
40 Le Fur G, Arnone M, Rinaldi-Carmona M, Barth F, Heshmati H (2001) SR141716, a selective
antagonist of CB1 receptors and obesity, 2001 Symposium on the Cannabinoids p.101
International Cannabinoid Research Society, Burlington, Vermont
41 Jensen M, Abu-Lebdeh H, Geohas J, Brazg R, Block M, Noveck R, Free R (2004) The selective
CB1 receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects.
Int J Obesity 28 (Suppl. 1): Abst T5:O2-001
42 Dale L, Anthenelli R, Després JP, Golay A, Sjostrom L (2004) Effects of rimonabant in the reduction
of major cardiovascular risk factors: results from the STRATUS-US trial (Smoking cessation
in smokers motivated to quit) and the RIO-LIPIDS trial (Weight reduction and metabolic effects
in overweight/obese patients with dyslipidemia). American College of Cardiology Annual
Scientific Sessions, Presentation 409-1, March 7–10, 2004, New Orleans
43 Houri M, Pratley RE (2005) Rimonabant: a novel treatment for obesity and the metabolic syndrome.
Curr Diab Rep 5: 43–44
44 Van Gaal L (2004) RIO-EUROPE: a randomized double-blind study of weight reducing effect and
safety of rimonabant in obese patients with or without comorbidities, European Society of
Cardiology Congress, Presentation 106, August 28–September 1, 2004, Munich
45 Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG (2000) Central nervous system control
of food intake. Nature 404: 661–671
46 Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M,
Bouaboula M, Calandra, Le Fur G (1998) SR 144528, the first potent and selective antagonist of
the CB2 cannabinoid receptor. The. J Pharmacol Exp Ther 284: 644–650
47 Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumption
decrease in CB1 receptor deleted mice. Neurosci Lett 343: 216–218
48 Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of the
Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist,
SR141716. The. J Biol Chem 278: 23731–23737
49 Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004) Evidence for an interaction between
CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology
145: 3224–3231
50 Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid
(CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in
rats. Behavi Pharmacol 13: 451–463
51 Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1
antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide
(SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement,
fixed ratio, and progressive ratio schedules of drug self-administration in rats. The. J
Pharmacol Exp Ther 306: 93–102
52 Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrie P (2001) SR141716, a CB1 receptor antagonist,
decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats.
Psychopharmacologia 157: 254–259
53 Kirkham TC, Williams CM (2001) Synergistic efects of opioid and cannabinoid antagonists on
food intake. Psychopharmacologia 153: 267–270
54 Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM (2004) Synergistic effects of cannabinoid
inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 999:
227–230
55 Croci T, Landi M, Manara L, Rinaldi-Carmona M (2002) Body weight curbing and respiratory
quotient lowering effect of the cannabinoid CB1 receptor antagonist SR141716 (Rimonabant) in
rats. IUPHAR Meeting, July 7–12, 2002, San Fransico, CA